Ladies and gentlemen, good day, and welcome to NATCO Pharma Limited's Earnings Conference Call for the Second Quarter FY 2027. We have with us on the call Rajeev Nannapaneni, Vice Chairman and CEO; Amit Parekh, Chief Financial Officer; Rajesh Chebiyam, Executive Vice President, Crop Health Sciences; and Rajeev Menon, Lead Investor Relations. Please note that all participants' lines will be in listen-only mode, and there will be an opportunity for you to ask questions after management's opening remarks. Should you need any assistance during the conference call, please raise your hand from the participant tab on the screen. While asking questions, please identify yourself and your company. Please note that this conference is being recorded. I now hand over the call to Rajeev Menon. Thank you, and over to you, sir.
Thank you, [Andip]. Good evening, and welcome everyone to NATCO's conference call discussing our earnings result for the second quarter of FY 2027. I am Rajeev Menon, Lead Investor Relations at NATCO. We hope you have received the earnings presentation and press release that were sent out earlier. Let me draw your attention to the fact that on this call, we may be making certain forward-looking statements, which are not necessarily historical facts. Anything said on this call which reflects our outlook for the future must be reviewed in conjunction with the risk that the company faces. We undertake no obligations to update these forward-looking statements.
I would like to state that the material of the call, except for participant questions, is a property of NATCO and cannot be recorded or rebroadcasted without NATCO's express written permission. We will begin with the financial highlights and then follow with an interactive Q&A session. With that, I request our CFO, Amit Parekh, to discuss the financial highlights. Over to you, sir.
Thank you, Menon. Greetings to everyone, and thank you once again for joining us in today's earnings call. The company recorded consolidated total revenues of INR 1,019.4 crore in quarter two FY 2027, compared to INR 794 crore in quarter one of FY 2027 and INR 1,463 crore in the corresponding quarter of the previous year. The quarter-on-quarter increase was primarily driven by the strong performance of our international formulation business. The YoY decline was largely attributable to lower lenalidomide revenue during the quarter, which was partially offset by the growth in the base business, which also includes our subsidiaries. EBITDA, including other income for the quarter, stood at INR 310 crore, with EBITDA margin of 30.4%. Consolidated profit after tax stood at INR 202.6 crore, compared to INR 206.5 crore in quarter one FY 2027.
With regards to our associate company, Adcock Ingram Holdings Limited, South Africa, the revenue for the quarter stood at INR 1,344 crore and profit after tax at INR 80.5 crore. In July 2026, we acquired additional 13.25% stake in Adcock Ingram Holdings Limited, taking our total holdings to 49%. This further strengthens our strategic position in South African market and enhances our participation in the performance of Adcock Ingram. NATCO's share of profit based on 49% holding as on 30th of September 2026 was INR 29.2 crore after adjustment relating to purchase price allocation. Our domestic formulation business revenue stood at INR 145 crore. We also saw strong growth in our Brazil business. Revenue from Brazil stood at INR 121 crore, representing the growth of 66%. Thank you all. With this, we will take questions and answers. Over to you.
Thank you, sir. We will now open the call for Q&A session. We will wait for a few minutes until the queue assembles. We request participants to restrict to two questions and then return to the queue for more questions. Requesting to please introduce yourself and your company before asking the question. Please raise your hand from the participant tab on the screen to ask a question. We will wait for a couple of minutes for participants to raise their hand and ask the question. The first question is from Shekhar Jain.
Hello, can you hear me?
Yes, Shekhar, go ahead, please.
Yeah. I am an individual investor, so I had two questions. In March, when we announced that we have a first-to-file status for pomalidomide, I was hoping for a bit of a bump. What happened with the pomalidomide first-to-file status? The second question is, what do we plan to do with the rights issue proceeds? Any color on that will be very helpful. Thank you.
Thank you, Shekhar. First question was on pomalidomide. We did get the first-to-file, Shekhar. I think we did, but it's a shared first-to-file. I do not remember the exact number of generic competitors. I think about five to six generic competitors came in the first wave. Because there were five and six competitors, the price erosion was quite steep. Even though we had 180 days, the earning bump was not substantial that could move the earnings. It is the way it is. That's the nature of the business. The second question is on the rights. I think we have multiple end-use requirements. I think primarily it's to reduce the debt that we have raised for Adcock. We are also keeping some money for the possible acquisition. We are looking at various acquisitions. That's the end-use expectation.
Okay. Thank you.
Thank you, sir. Next caller, please.
The next question is from Bhuvanesh Bhoomi.
Sir, am I audible?
Yeah, please go ahead.
My name is Bhuvanesh. I'm an individual investor. I think as of now, Revlimid sales is exhausted. What's the next big shot drug in our pipeline?
I think we have few launches that are coming up in the next few quarters. One is definitely carfilzomib launch is there. It is coming up in the next few quarters, and then of which one strength we have first-to-file, 60 mg is shared, what you call first-to-file. Then we have trabectedin coming up, which is a smaller product, but we are one among the two first-to-files. Then we have these are two major ones in the U.S. Then we are expecting launch of olaparib also in the next few quarters in Brazil and Canada. So these are the major launches coming up in the coming few quarters, subject to launch and legal challenge. Yeah.
S ir, what is the plan about spinning off our agri-fertilizer business going forward?
Yeah. Hi, Bhuvanesh. This is Rajesh. So I will answer that. See, as you are aware, we did a rights issue, which basically what it does also, the CapEx structure is now changed a bit. Because of that, we have to resubmit the file to SEBI. So it pushes out by four to six months from the original plan. So we are looking at maybe by mid-year; calendar year next year is when we hope to get the demerger done. Okay?
Yeah. Thank you, sir. Thank you.
Thank you. Next caller, please. Yeah.
Thank you. The next question is from Ramakrishnan.
Yeah, please go ahead, Ramakrishnan. I think you are on mute.
Yeah. What are the plans regarding the QIP?
We have done the rights issue, Mr. Ramakrishnan. We have not done QIP. We already completed our rights issue.
Yeah.
Essentially, we used the funds to reduce some debt that we had, and we kept some money for some working capital payments and for a possible acquisition that we are looking at.
T he QIP makes the equity diluted, no?
It is already done, Mr. Ramakrishnan. It is already done. Rights is already done. I think this was done last month, so it was already completed. There is a dilution, yes. There was a dilution, but we gave opportunity for all the shareholders to participate.
D oes—
There was a dilution of a. Yeah, sorry.
Sorry. Does QIP bring more dilution?
It is already done. The dilution is done. We have done a 10% dilution overall. It is already done.
My next question is, this is related to the stock performance. What is happening is PE is still quite low as compared to the equal or maybe less market capitalization companies in this segment. What steps you are taking? I mean, perhaps and general observation is communication; broad market communication is still not up to the mark. Are you making any steps like appointing a separate person exclusively for corporate communication so that positive things will be communicated to the market so that market takes in the right spirit? What is happening is, I have been observing last I mean, if you look at five, six years, returns are practically nil or negative. The important factor for any company to grow is to take care of the investors' interests also. That is the only way.
When you want to increase the capital, when you want to go for further expansion or acquisition, the only possibility is proper value to the shares. Then the dilution will be low. What steps you are taking? I think you need to apply mind more seriously on this subject as you have been doing on the products.
Mr. Ramakrishnan, I like to differ with you on this. I think if you look at our model, it's a high-risk, high-return model. If you look at our earnings in the last five years, I think we had probably the best earnings in the industry. If you look at the top 10 earnings in the company, and among the pharma listed space. There is a lumpiness in our earnings, and I think which has been always communicated to our shareholders.
No, s orry to interrupt.
Mr. Ramakrishnan, you asked the question. Let me answer your question. I gave you an opportunity. Give me two minutes.
Yeah.
There's a certain level of lumpiness that is there. I think what we try to do with our investors and when we engage, we have a dedicated IR team that we engage, and we mention what upsides we're looking at and what are we chasing. We have done that in a regular fashion. If you look at whatever is there in first files, or our investments in eGenesis, for example, which has done the first kidney transplant in human-made from a pig. These are all very exciting, high-risk ideas. There's an amount of lumpiness. Regarding PE ratios, this is my personal opinion because you asked me this. I think the market appreciates more steady earnings, which are low risk, and they give a higher multiple for that. I think our market is unwilling to appreciate high-risk, high-return sort of ideas.
I think our job is only to communicate what we're doing. I don't look at stock price. We look at the logic of the company. We look at our earnings in the last four or five years. I think the part of our earnings has been substantially larger than a company which has a higher PE. I think just look at the math. I think we have done well. This is the nature of our business. I think our job is only to tell you what we do, and I think I don't control stock prices. I think our strategy is this way, and this is how we run our business.
See, but ultimately, return on investment is also equally important.
See, return is also important, governance is important, strategy is important. I think all these communications are done in a fair manner. In the end, I think you just have to This risk appetite is based on the investor's perception. I think that I can't control. Okay? That's the best I can. Thank you. Next caller, please.
Thank you. The next question is from Rashmi Shetty.
Hello. Am I audible?
Yes, Rashmi. Please go ahead.
Congratulations on good set of numbers, sir. Sir, just wanted to reconfirm that whatever guidance you gave in last quarter, that FY 2027 revenue should be in the range of INR 34 billion-INR 35 billion, and PAT should nearly INR 700 crore-INR 750 crore. Do you still hold that? And you feel, because in the first half, we have done around INR 400 crore of PAT.
I think we can do better, Rashmi. I think where things are going right now, I think we will probably be a little less than INR 800 crore of PAT. I think we will like to bump it up a little bit. I think it will be between INR 775 crore -INR 800 crore is what I feel. Q3 also looks good. I think Q4 is a little weak, but at least from what I can see. But for the year, I think we should do, I think, a little less than INR 800 crore. So I think we will probably do better than what you start the year.
T his will be largely driven by which of these segments, if you can talk on domestic business, even Brazil, earlier you mentioned that you will be able to achieve sales of $55 million-$60 million this year. But I think in this quarter itself, we have done so. How much, if you can give some breakup, in first half, what we have done in the subsidiary, that is Brazil, Canada, rest of the world, U.S., and then how should we look at it for the full year?
I think, see, in terms of Brazil and all, for the half year, I think we have done nearly INR 300 crore of revenue in Brazil. We do not do a geographical split for Brazil. I think we are doing because we have our own sub. In terms of the earnings itself has not come concentrated manner like the way it used to come in the previous financial years. I think it is fairly diversified. I think a good portion has come from South Africa, a good portion has come from Brazil, good portion has come from the base U.S. business, and this has come even without lenalidomide being in the numbers. So I think that way, it is a more well-diversified earnings. I think in the past, the challenge has been that the earnings have been so concentrated by lenalidomide.
Anything else that used to do well also would pale in comparison to lenalidomide. I think that change you could see in our earnings now. I think it is relatively more diverse.
Sir, in your base U.S. business, you have seen better traction in the volumes as well as pricing, or you are seeing a better pricing and that is driving the entire growth?
U.S. is a tough bet, Rashmi. I think U.S. is the most important market in our generics business. You cannot ignore it, but at the same time, we also need to see that sometimes you could be in a product and you can make a lot of money, and sometimes when there are more competitors, there is obviously no margin. But you have to run the basket game, and you just have to be patient, and there are always opportunities that come. But U.S. still, in my personal view, is always a good business if you have limited competition. It is not a great business when you have a lot of competitors.
That has been the case, and you just have to be patient with that business. But overall, I think relatively the rest of the world is a more stable business compared to U.S., but you cannot ignore U.S. I think that is how it goes.
Understood. Just last question on the operating margin front. This is the kind of margin which is sustainable, right? Whatever we have done in first quarter and in second quarter.
I think so, Rashmi. I think where things are going, I think, yeah, this is a sustainable base. Yes, absolutely.
Okay. Thank you, sir. That is it from my side.
That is it. Thank you so much. Yeah. Next caller, please.
Thank you. The next question is from Rahul Chaudhary.
Hi. Good evening, sir.
Good evening.
I was looking at the cash flow. There's a dividend from associate INR 78 crore. Has that come from Adcock?
Sorry, what's your question? Can you repeat?
He said profit from associates. I think first quarter, INR 80 crore it came from the-
You're right.
It's come from Adcock.
Yes.
You can go on with your next question, Rahul, or we will go to the next call. Okay. We will go to the next call. Thank you.
Thank you. The next question is from Abdul Puranwala.
Yeah. Hi. Thank you for the opportunity. My first question is with regards to your quarterly run rate in India. I know that has been growing quite well. So wanted to understand whether it is entirely driven by semaglutide, and in terms of this Onco price cut, how do we see that getting impacted our India growth ahead?
The Onco price cut itself is not impacting our sales too much, because a lot of the distributor margin has been shrunk. So it is not affecting the company. So I do not see much impact. There could be a small marginal impact, but it will be more than made up by the volume increase. And the first question you had was what? I just forgot. What was it?
Yeah. On the run rate front, is it mainly driven by semaglutide?
Run rate, we had some stocking quantity of semaglutide to our partners. That's the reason why it's a little bit higher. Domestic is like, I would say, about 130 - 135 would probably be the base domestic, is what probably we're running at.
[crosstalk].
This particular quarter was 145, but I think there's a little bit of stocking of semaglutide, which it's not going to be repeatable. So, I think 130, 135 is the base domestic now. I think that's the sense, based on the present portfolio.
Okay. Yeah. And, sir, second question I had with regards to your R&D spend. This quarter, if I see your other expenses has gone up, safe to assume it would be mainly because of R&D, and if you could quantify that amount for this quarter, versus what you were doing last year for FY 2026 would be helpful.
Abdul, largely the reasons are primarily R&D spend itself. But there are a couple of other spends as well, like annual FDA facility fees and program fees are also there, and there are some legal expenses, et cetera. But large portion of the increase is R&D. That's how I'd put it.
Okay.
R&D is very unpredictable. Quarter -on -quarter, it depends on the milestone, what we achieve in the program, et cetera. Compared to last quarter, this quarter, the R&D spend has been substantially high.
Yeah. What I was trying to understand basically is that from a full-year perspective, are we seeing that trend increasing in terms of the run rate, what we were at last year, and in terms of, say, some additional products entering into the pipeline or into development that is fueling this increase?
I think the run rate. Overall R&D spend, the way we look at it, and most of the pharma looks at it as a percentage of the sales. Last year, obviously, our R&D spend was more than INR 400 crore. This year, overall, it would be 8%-10% of our top line. We may end up around INR 300 crore-INR 350 crore, depending on how the program runs. Yes, there will be. Quarter one was a little lower spend. Quarter two is high. Even I think I'm expecting quarter three to be a little higher in R&D, but other spend will be moderate. Quarter four would be okay. This is how I would look at it. I hope I've answered your question.
Yeah, sir, that helps. And, sir, I had a couple of more, if I may. Just one on your profit share from Adcock. If we look at the annualized run rate versus this particular quarter, the run rate looks a little lower. I went through the press release, it talks about certain provisions. If you could quantify and help us understand what can be the steady state run rate.
Right. Sure. There are two reasons for lower number in the quarter. One is, quarter one profits from Adcock was very high, and that is a seasonal effect. There was a flu season in South Africa, because of which quarter one is the highest quarter for the South Africa companies, and that's the reason the major portion came in from there. This quarter, obviously, we had the additional acquisition of 13.25%, and we had to purchase price allocation. There's a one-off amortization because of that allocation, which is around INR 6.5 crore.
Plus there was also a bit of VRS in one of the facilities. That also there was a one-time charge. The way you want to think of it is, it's probably a $12 million per quarter kind of setup. I think $12 million-$14 million, depending on the seasonality of the quarters. But I think, what, $12 million seems about right, I think.
We get 49% of it.
We get 49% of it, a little bit of amortization. [ 4, 5 crore amortization ].
Yeah.
Yeah. So you should, if EBITDA is about $12 million, I would say $6 million pickup, out of that $6 million, maybe 4, 5 crore amortization. So INR 55 crore-INR 60 crore sort of consolidation should look in our-
Understood. Very helpful. Sir, last one, if I may. This is with regards to your investment in eGenesis. So I believe there is some additional investment being done. So now what is our stake currently? In terms of, if you look at the trial data, after the phase III trial, how do we plan to commercialize this opportunity? Whether it would be kind of an out-licensing deal which can happen, or you may look for a partner to kind of take that ahead?
Regarding stake percentage, I am not supposed to disclose. It is a substantial single-digit stake, so that is all I can say. In terms of, we have put about little less than $25 million into the entity. In terms of how do we expect to monetize, I think there are multiple ways. One is we are asking for a license for the India market, so that discussions are ongoing. If we get a license, that would be one way of monetizing the asset. Second, obviously, is the company were to go IPO, so that is another way of monetizing the asset. I think a lot of it will revolve around how the asset does in the clinical trial. I think we have one patient who is approaching almost one year now without dialysis.
If that readout looks good, and then we have more patients coming in, then I think we are sitting on a jackpot. Let us see how things go. These things are, again, very high risk, high return. We just have to be patient how things go. I think next 12 months, I think we will have clarity on the data. So far, so good. I think that is all right. Next call.
Got it, sir. Thank you.
Thank you.
Thank you. The next question is from Ruchi Sethia.
Hello, am I audible?
Yeah, please.
Yes.
Yeah, my question is around what is the volume share that NATCO is looking for the semaglutide market?
In the India market, you are saying, Ruchi?
Sorry?
In the India market, how much share we have—
Yeah
—volume?
Yeah, the India semaglutide market.
I think pen has not done so great. The vial has done better. I think if in terms of volume, I am just making an estimate. I mean, it is an educated guess, right?
Yeah.
I would say we have probably about 5%-6% share in terms of volume. In value, maybe we only have like 3% share. I think that's my estimation. I think, again, I'm going by approximate estimates.
Yeah, can you give a percentage split between the vials and the pens?
I'm sorry, just say that again.
Can you give a percentage split between the vials and the pens?
Percentage split, I cannot recollect. I think the brand does like INR 1.5 crore-INR 2 crore a month, depending on the month. I would say INR 40 lakh-INR 50 lakh comes from the pen, and I think about INR 1.2 crore-INR 1.5 crore comes from the vial. The vial is obviously much cheaper, so I think obviously the more volume we get from that. I think that is
Okay, and given the number of generic entrants that we have had, what is the percentage of patient months that we have seen a change in realization per patient?
It has been pretty crappy, Ruchi. I think it has not been great, honestly. I think everybody is trying to get market share, so the pricing has been really bad. I think everybody is hoping that you just stick in there and then hope get that 5%-6% share and just hope that the wave gets better over a period of time, the next two to three years. And then as the market size of semaglutide increases, you keep your market share, and then as the size increases, you benefit from it.
I think that is the hypothesis all of us are working on. I think I am no different. I think we made a dent. I think we are there. But is it profitable? No. And do I see any profits coming in the near future? No. In the long run, maybe. I think it should do well as the size of sema increases. Yeah.
Okay, got it. Thanks.
[inaudible].
Thank you. We will wait for a few minutes until the queue assembles. Raise your hand from the participant tab on the screen to ask the question. Next question is from Gagan Thareja.
The first question is on your working capital and tax rate. I think it would help if you could give the working capital in days sales and enumerate the inventory debtors and payables, and what could be the sustainable tax rate going ahead?
Let's take that question. First question was on the tax rate, and second is, what did you Again, your voice was very soft, so we couldn't pick up what you said. Tax rate, we understood. And then can I ask, do you want data, as you said?
Yeah, I want the working capital. I believe working capital has increased YoY in days sales. Can you give the number in days sales for working capital?
Right, I will take that. I think our tax rate for the quarter is around 27% in India. Overall, I think it is around, on consol level, it is around 29%. We expect, and this variation comes because of the subsidiary profitability mix. We expect at overall level, on a full year basis, our standalone tax rate would be around 27%-27.2%, and at consol level, it may be ranging between 29% - 30%. Coming to the working capital, yes, I think, it is a mix of, if we just look at from our India business perspective, I think the DSO would be between 90 - 120 days, and that is the range we expect to continue.
Next caller, please.
Hello.
Yeah, please go ahead.
[inaudible]
[crosstalk].
Yeah. I have one more question, and I think you gave some commentary on Canada, but can you also Sorry, you gave some commentary on Brazil. Can you also give some flavor of how Canada and the other ROW markets have done for you in the first half of this year, and how do you expect the other geographies in ROW to pan out for the balance of the year?
I think ROW business, especially the MENA region, has done well. Canada has been stable. It has not increased, but we have some big launches coming up in 2027. We expect 2027 will be a blowout year in Canada. Brazil also continues to do well, and I think we had almost 80% growth in Brazil-based business this year. We expect that it will continue to do well next year. I think Brazil, Middle East, and Canada will drive our rest of the world business. Of course, the U.S. exclusivities are also there, so that will also help us. Thank you. Next caller, please. Next caller, please.
Yes. Thank you. I have one more if I can go ahead or—
Okay, fine.
Yeah. Thank you.
No, I just give. You can come back again if you don't mind. Okay. Thanks.
Okay. All right. Thank you.
Thank you.
Thank you. The next question is from Shekhar Jain.
Thank you for the opportunity again. You gave some commentary on the semaglutide market in India, which was very helpful. Can you comment on the semaglutide market in the rest of the world? If you are looking to expand to rest of the world? That is one question. The second question is about our upcoming launch on carfilzomib. I am a bit confused because different companies seem to have sole exclusivity status for different strengths. Why does that happen?
I will explain. Let us start with carfilzomib. There are three strengths in carfilzomib. Majority sale is the 60 mg. There is 60 mg, there is 30 mg, and there is 10 mg. 60 mg has, I think, I do not remember exactly, about six filers, I think, or multiple filers. I cannot remember the exact number of filers, but there are multiple filers. Even though we have 180 days, it has multiple filers, the value of it will not be that exciting. On the lower strengths, one strength, we have sole FTF. That is the one that we intend we will do well. The other strength we do not have exclusivity, so launch will be later after the first wave of launch. That is how it is.
Yeah. My conclusion is, why does not a company apply for FTF in all the strengths when it does the application?
No idea. There was a quirk there, Shekhar. Basically, what happened was, 60 mg was the first product that was launched. Everybody applied on NCE-1 date when that product was filed. But 30mg and 10mg got approved much later. Because it got approved much later, anybody could have filed. There is no date limiting. Whoever files first will get it. It was a race, so the single winner. NCE-1, what happens is, if everybody files on day one, then everybody gets it. That is why 30mg and 10mg was later. Because it was later, that is the reason why there is no multiple FTFs on 30mg and 10mg.
Okay. Thanks. Any comments on the global semaglutide market? Is it as competitive?
We are not. Like the way our contract is written, we are not focusing on ROW. I think our focus is primarily on U.S. and the regulated market. Yeah, U.S. filing, we are answering the queries, so we can't give any insight about our approval. But I think, at this time, we are continue to pursue our regulatory queries. So I have no insight to give at this time.
Thank you. That's helpful.
Okay. Thank you. Next caller, please.
Thank you. The next question is from Kunal Randeria.
Hi. Good afternoon, Rajeev. Rajeev, you said your domestic base business is around INR 135 a quarter, right? Till last year, I had understood it was around [inaudible] a quarter. Is this a sustainable number, and what has driven this?
Kunal, we have done well. I think one is semaglutide has helped. Getting 6, 7 crore in semaglutide, and rest of the time has done well. That is also helping us. Overall, our base business has done much better. I think you have seen a good 20% bump in our domestics. Even if you remove the one-offs of semaglutide stocking quantity, I think as a whole, our domestic business has improved dramatically. Yes, you are seeing the value of that. You are seeing the value of the business.
That is good to hear. What do you think of sustainable growth rate going forward?
I think the internal target is based on what we have planned. We feel we can compound another 15%-20% next year also.
Oh, wow. That's good to hear. Secondly, Rajeev, and apologies if you've answered this, there was almost a INR 200 crore increase in international generics business. Is there an element of tender or one-off or anything in this?
Yeah, there's an element of. The base is around INR 800, Kunal. Then the INR 100 was a one-time sale, yes.
No, sorry. You did INR 660, right? INR 660 in the quarter, right?
No, I am saying consol numbers. Consol numbers are about INR 1,000. So, what I am saying is that base is around INR 800, INR 850, and then we always get these one-times, so that is why it is up to INR 1,000. Base is around INR 850, INR 900. I think that is what it is.
Got it. And just one more thing, please. So obviously, you shared the Crop Health Sciences revenue contribution, but in terms of EBITDA, the loss quantum, if you can. And secondly, are we on track for the demerger by the end of this fiscal?
Kunal, can you say that again? I did not catch anything you said. Can you repeat the question?
Apologies. Yeah. So I was asking you about the agrichem business. What will be the EBITDA contribution?
EBITDA for the half year? Rajesh, you can answer that question.
Yeah. So, in fact, this quarter, we just slight marginal profitability. So, that's about, literally from a segmental perspective, about INR 10 lakh profit on that. So, that's what we have. So compared to Q1, this is a positive quarter for us. But having said that, Kunal, again, there are multiple things we are also battling, few other credit-related provisions that we have taken. So from a business perspective, I would say last year to this year, about 15%-17% growth. But our aspirations were even much higher. And as you know, there's the El Niño and effects related to that was quite horrendous. So all in all, I'd say the quarter is positive. And looking ahead for the year itself, we are quite positive compared to the last year, in terms of maybe around 15%-20% growth.
Got it. And the spinoff, is it on track for this end year end?
Yeah, I think we mentioned this earlier on. Because we had the rights issue and then some recapitalizations happened, so we are going back to SEBI for the filing, and then there's an NCLT process. So we are estimating mid-calendar year 2027 for the demerger.
Got it. Thanks. You all the best.
Thank you.
Thank you. Anyone who wishes to ask the question, please raise your hand from the participant tab on the screen. The next question is from Subhash Gupta. Hi, Subhash. Requesting you to unmute yourself. We will go to the next caller. The next question is from Rahul Chaudhary.
Hi, am I audible?
Yeah, please speak up a little bit, Rahul.
Yeah. I just wanted to know something about our Para IV pipeline. I am sorry, I might have missed it earlier. With regarding to Ozempic, we have settled with the innovator, but have we got everything else from the regulator? So that whenever we are
Rahul, I think, yeah, we do not have an approval yet, Rahul. We are answering some queries from the FDA. Subject to us answering the queries and getting the clarity from the FDA, then we can speak about our exclusivity. But at this time, we do not have approval.
What about Imbruvica? There also, it continues to be listed in our presentation, but there also, we have hit a hurdle, isn't it?
No, no. It is done, Rahul. Settled.
Okay.
It is settled, and we got it approved in 30 months, so we, yeah, the exclusivity is. We believe the exclusivity is there, so no problem there. That is sorted. That is covered.
Sir, I just also was looking at the cash flow statement of H2. So, there is a dividend received from an associate. So, is that Adcock?
Yeah, you are right. It is from Adcock. Adcock has been announcing dividend also, so we get that coming to us.
Right, sir. I mean, you have always told us that 26/27 is going to be a very low-key year, and the market is still, I think, valuing it as 19-20 PE. Anyway, leaving that aside, what is the outlook for 2027, 2028? Do we have any big launches coming up which you may not be able to
I think we mentioned that, Rahul, I think we mentioned about, I think in the coming few quarters, we expect about three products, carfilzomib, trabectedin, then olaparib. These are the major launches. Based on how they do, I think that will drive the earnings.
My last query was—
Yeah, sure. Yeah.
With regard to this South Africa company now that we have acquired, are we moving ahead with launching anything in the African market?
We are working on it. We have actually filed multiple products. It has been about one year since we bought this company. We have made multiple files. Regulatory approval takes about two years, two, three years. I think we will see the value of our portfolio coming in the next one and a half, two years. But now the regulatory approval process is ongoing. We believe, I think we will see the value in the next two years.
Sir, any new Para IV thing that we have filed or we are waiting? I mean, how does that happen, sir? Because R&D is happening continuously.
Rahul, we are targeting some Para IVs, sole FTFs. We are targeting something. Hopefully in the next few quarters, we get the position and we will declare. But as of now, I have nothing to do.
Okay. Thank you, sir. That's all.
Thank you. The next question is from Digvijay Patil.
Yeah. Hi. Thanks for the opportunity. I just wanted a couple of strategic clarifications. First is, we have announced a dividend. I just wanted to understand the rationale behind the dividend, given that we have just raised funds. Second, that our debt is coming up in INR 100 crore tranches every quarter, I think. Do we plan to prepay it upfront or are we planning to prepay it every quarter as and when it comes due? The third question is on the acquisition. What would be the price to earnings or some flavor of the value of acquisition that we plan to do given that we have just raised funds?
Let me answer your first question, the dividend question. We've been giving steady dividend, Digvijay. This is no different from what policy we've had in the past. I don't think we are really. Raising the funds is not anywhere linked with the dividend. The steady income that we give out to shareholders, and that's we continue to do that. Regarding acquisition and all, I mean, you're looking at different assets. Hopefully, we'll be able to close something. We look for value for money. You don't have a target PE that you can talk about, but you look for value for money, and we are not in haste to do a transaction. You had another question.
In terms of the loan, yes, as of September 30, we did have loan. But once we raised the funds, we have repaid the entire loan. As of today, we don't have any loans right now.
Sure. Thank you. The PAT guidance that we have given, that would include the interest saving and the demerger, which would be probably PAT dilutive right now, like a loss at the PAT level, right?
Demerger is not going to happen this financial year. The loss of the agrichem business will be in the earnings. We expect that the agro business will lose about INR 20 crore at EBITDA level. That is already embedded in the earnings. When we give a PAT guidance, the loss of the agro is part of the PAT guidance. And the interest income is also included of the money that we've discussed.
Sure. Thank you.
Next caller, please.
Thank you. Next question is from Arjun Krishna. Hi, Arjun. Are you audible?
[inaudible].
I think there is some audio issues with Arjun. The next question is from Gagan.
Hello. Yeah. Thanks for the follow-up. I just wanted to get some idea from you regarding your ROW outlook for the next year. This year will be a strong one, clearly. How do you foresee FY 2028 for ROW? Also, based on the launch pipeline in U.S., what sort of growth can we envisage in U.S. for next year?
I think overall, we believe that our business should grow. I think we're giving I don't want to give a guidance for March 2028 yet. I think I want to wait till the end of the year. But we expect to grow around 10%-15%. I think that's our expectation. But I think we'll more precise guidance will give, I think, closer to the end of the financial year. It'll be driven by our ROW and our U.S. business. But I think we'll give you more clarity, I think, closer to the time.
Yeah. If I refer back to your commentary at the start of this financial year, you had indicated that FY 2028 and 2029 could be strong years for NATCO post 2027.
Right.
If you're targeting 15% top line growth, is there potential for margin improvements which lead you, I mean, to believe that these two years could be strong?
I think the challenge here is that, see, that is driven by the base business. I think all the upsides of our investments that we made or Para IVs that we made that we could possibly monetize are over and above that. I think that is not included in that. Because those are all very uncertain. I think that we are not including that. We are just driven by the certain outcomes we are giving guidance on. But any one-times or exclusivity or any upsides from the investments, that we are not including. It is tough to judge, and I will be very honest with you. As much as we like to give guidance for the future years, I think you can have more clarity only when you are closer to the year. We can only make a positive judgment that it will go in a particular manner.
I prefer to talk about it closer to the end of the financial year. At this time, I think I will have more clarity, and it will be easier for me to judge. Okay? Thanks. [inaudible].
Thank you. The next question is from Rajat Srivastava.
Yeah, hi. Am I audible?
Yes, sir. Yeah, please go ahead.
Yeah. Hi, Rajeev. Rajeev, just one question. In the cash flow statement, I can see that there is some INR 300 crore CapEx already done in the first half, which looks quite high if I compare it to last year. Can you tell us where is this CapEx going, and if you could just share the CapEx guidance for full year?
I think we target about INR 400 crore worth of CapEx every year. I think most of the CapEx is going at We are upgrading our Chennai and Mekaguda facilities, our API facilities. Our API new blocks we have built, so that has taken away most of the cash. We are also upgrading our formulation facilities. We added a new oncology line in our Nagarjuna Sagar site, just coming to market. We just started production now. Also, we are setting up a cartridge line to make semaglutide internally. That CapEx is also ongoing. That line will get ready next financial year. And general basic maintenance CapEx. Our run rate is around 400 a year. I think typically we spend about 350-400. This year we spent a little more in the half year. But yeah, that is mostly how we do things here.
Sure. Thanks.
Sure. Thank you.
Thank you. The next question is from Aman Hasan.
Hello, am I audible?
Yes, Aman. Please go ahead.
Sir, my question is regarding our associate Adcock appointed a new CEO. What are the strategy? Can you tell us?
Say that again. I did not understand. Can you repeat that question one more time?
Our associate Adcock appointed new CEO.
Oh, yes. Of course. Yes. What about him?
What is the upcoming strategy? I want to know.
He is Mr. Rhulani . He has been appointed recently. He comes from very good experience in Innovator Pharma. I think he was with Pfizer, I think was his last job before he joined us. He is a good person, and I think he has a lot of experience in prescription business, which has been the weakness of Adcock. I think after he came in, I think we have seen a lot of uptick, and also other colleagues who have been recruited recently. I think we have seen an uptick in the prescription business. I think that is the strength that they have. We are happy with how things are going.
Yes. My second question, I had read a news regarding Adcock shutting down its plants because of non-profit product.
They have laid off some people recently in one of the lines, I think, because that one-time charge is already reflected in Adcock's earning. Yes. This one particular factory has happened. Yes, that's correct.
Yes. My last question is, how big we take acquisition? How is big?
Right now, our position is that we own 49% of Adcock, and I think that's our position at this time.
What is cash in our book?
As of today, after the rights issue, Amit can answer.
Yeah, as of today, if we consider the rights issue inflows, we are around INR 2,250 crore.
Net cash.
Net cash.
Net cash. And how big is transaction which we acquire?
New acquisition.
You mean Adcock's 13% or future acquisition?
No, no. Upcoming acquisition.
We don't know. I mean, we're shopping for different transactions, so we expect to use some portion of this cash to do this transaction.
Okay. Thank you.
Thanks.
Thank you. Please raise your hand from the participant tab on the screen to ask the question. The next question is from Subhash Gupta.
Good afternoon. Can you throw some light on the commercialization of NRC-2694? Any timeline to it? As well as
As of now, no, Subhash. I think we are still trying to redo the strategy. We've done some phase I data, so I think now we're trying to see what the right strategy is in terms of what our phase II strategy should be. At this time, I have nothing to report.
My second question is with respect to the performance in this quarter. If you look at the performance excluding the associates, there has been substantial improvement in profit before tax. It has almost doubled over the previous quarter. Is this sustainable?
I think, Subhash, our business has cycles and it has different territories do well in different times, and there's also an element of one-time orders that you get, tenders that you get. When we give a guidance, we give it for the whole group. I don't give it for one particular entity. Sometimes India does well, sometimes Canada does well, sometimes Brazil does well, sometimes U.S. does well. Generally, when we give a guidance, we don't try to capture volatility that happens in each market. When we give a guidance, it is netting off all the ups and downs that we have. I wouldn't want to look at it on a quarter-to-quarter and entity-by-entity basis. You should look at the whole year to get a better understanding of what happens.
My final question is with respect to acquisitions. Are we thinking of concluding any acquisitions in the current financial year, whether in India or abroad?
We are trying, Subhash . We are trying one transaction. We are running it, I think, quite seriously. Hopefully, we will be able to close it. But again, it is all subject to all the regulatory and all the agreements getting done. But we are, yes, we are actually trying to do one more transaction. That is good.
Thanks a lot. Thank you.
This will be the last caller. Thank you, whoever it is.
Thank you. The last question is from Digvijay Patil.
Yeah, sorry for coming back in the queue, but I just wanted some clarity that you just mentioned about the acquisition. Prior to the rights, did we have any bankers set up for doing an M&A transaction, or are we doing it after the rights closure, or how is that timeline going?
We are always looking at transaction things, which is no, like, nothing is linked with rights. Rights is a parallel process, and then the engagement for transaction is a parallel process. I think we spent, if you look at it, in the last two years, different transactions we spent last four or five years we're taking, including NATCO, we spent nearly INR 3,500 crore in acquisitions. This has helped us set up a front end in the U.S. We have able to build a reasonable front end in South Africa. Obviously, South Africa being the biggest chunk of that money. I think this is always an ongoing process. You look at multiple transactions, but in the end, you only consummate one or two. That's how it goes.
Just a thought on the acquisition, why not purchase the entire stake of Adcock? We have 51 pending there. That seems like a target that we can directly acquire right now.
I would love to consolidate, but at this time, only 49% was at offer, so that's why we are here. Hopefully, if the major shareholder chooses to do it, then we'll come. At this time, it's not at play, but certainly, I think if they are interested, we are also interested. At this time, only 49% is at play, so that's what we bought. I think the asset is so valuable that 49% also is very meaningful. That's why we took it.
Sure. We have the first right of refusal, right, there?
[crosstalk].
At this, I will end the call. Yeah. Again, thank you very much. Thanks for your questions.
Thank you. Passing the call to Rajeev Menon for the closing remarks.
Thank you, everyone, for joining today. If there is any question unanswered, please reach out to the Investor Relations team. Thank you.
Thank you very much to NATCO's management team. Ladies and gentlemen, on behalf of NATCO Pharma Limited, that concludes today's conference. Thank you for joining us, and you may now disconnect your line and exit the webinar. Thank you.